德罗克西多巴在重症监护中:对新兴的非标签实践的系统审查
Carlos Valladares1, Franklyn Vega Batista2, Marc Faltas3
1Department of Pulmonary and Critical Care, University of Miami, Miami, 33136, Florida, USA, miami.edu.
Critical care research and practice
|December 22, 2025
概括
德罗克西多巴可以帮助重症监护室 (ICU) 患者摆脱血管压缩剂,但目前的证据有限. 需要进一步的研究来确认其在重症患者群体中的有效性和安全性.
科学领域:
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 在重症患者中长期使用静脉注射 (IV) 血管压缩剂与严重的并发症有关.
- 作为一种北上腺素前体的德罗克西多巴 (Droxidopa) 正在探索在重症监护室 (ICU) 促进血管压缩器断奶的可能性.
研究的目的:
- 系统地审查droxidopa在ICU患者的血管压缩器断奶的疗效和安全性.
- 综合当前关于droxidopa在治疗需要血管压缩剂支持的重症患者中的作用的证据.
主要方法:
- 根据PRISMA指南进行了系统审查.
- 搜索的数据库包括到2025年4月的PubMed,Embase,Cochrane和科学网.
- 包含的研究报告了ICU患者使用德西多巴的初级临床数据,评估了诸如血管压缩剂中止的时间,德西多巴使用的持续时间,ICU停留时间 (LOS) 和ICU死亡率等结果.
主要成果:
- 包括7项研究,包括161名ICU患者.
- 停用血管压缩剂的时间从29小时到120小时不等;用德洛克西多巴的持续时间从87小时到192小时不等.
- 这些发现是基于小型的回顾性研究,由于剂量和结果报告的差异,其概括性有限.
结论:
- 德罗克西多巴可能有助于危急病患者的血管压缩器断奶,但证据有限,确定性非常低.
- 研究设计,患者选择和结果报告的异质性需要谨慎的解释.
- 需要进一步进行高质量的研究,以确定droxidopa在ICU血管压力控制中的最终作用.
相关概念视频
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Drug Dosing: Obese Patients
195
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
195
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
186
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
186
Adrenergic Agonists: Therapeutic Uses
1.6K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.6K
Drug Dosing: Infants and Children
229
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
229


